Explore our ongoing and completed clinical trials below.
| Clinical trial | Phase | MOA | Disease state | Investigational therapy | Associated publications |
|---|---|---|---|---|---|
|
Topical roflumilast cream (ARQ-151) atopic dermatitis study in pediatric patients (INTEGUMENT-PED) Completed |
Phase: 3 | MOA: PDE4 inhibitor | Disease state: Atopic dermatitis | Investigational therapy: Roflumilast cream (ARQ-151) | |
|
Topical JAK1 inhibitor cream (ARQ-252) phase 2a nonsegmental facial vitiligo study Terminated |
Phase: 2a | MOA: JAK1 inhibitor | Disease state: Vitiligo | Investigational therapy: JAK1 inhibitor cream (ARQ-252) | |
|
Topical JAK1 inhibitor cream (ARQ-252) phase 1/2b chronic hand eczema study Completed |
Phase: 1/2b | MOA: JAK1 inhibitor | Disease state: Chronic hand eczema | Investigational therapy: JAK1 inhibitor cream (ARQ-252) | |
|
Topical roflumilast foam (ARQ-154) phase 3 seborrheic dermatitis study (STRATUM) Completed |
Phase: 3 | MOA: PDE4 inhibitor | Disease state: Seborrheic dermatitis | Investigational therapy: Roflumilast foam (ARQ-154) | |
|
Topical roflumilast foam (ARQ-154) phase 3 scalp and body psoriasis study (ARRECTOR) Completed |
Phase: 3 | MOA: PDE4 inhibitor | Disease state: Scalp and body psoriasis | Investigational therapy: Roflumilast foam (ARQ-154) | |
|
Topical roflumilast foam (ARQ-154) phase 2b scalp and body psoriasis study Completed |
Phase: 2b | MOA: PDE4 inhibitor | Disease state: Scalp and body psoriasis | Investigational therapy: Roflumilast foam (ARQ-154) | |
|
Topical roflumilast foam (ARQ-154) phase 2 seborrheic dermatitis phase 2 study Completed |
Phase: 2 | MOA: PDE4 inhibitor | Disease state: Seborrheic dermatitis | Investigational therapy: Roflumilast foam (ARQ-154) | |
|
Topical roflumilast foam (ARQ-154) phase 2 seborrheic dermatitis long-term safety study Completed |
Phase: 2 | MOA: PDE4 inhibitor | Disease state: Seborrheic dermatitis | Investigational therapy: Roflumilast foam (ARQ-154) | |
|
Topical roflumilast cream (ARQ-151) phase 3 plaque psoriasis study (DERMIS-2) Completed |
Phase: 3 | MOA: PDE4 inhibitor | Disease state: Plaque psoriasis | Investigational therapy: Roflumilast cream (ARQ-151) | Associated publications: Effect of Roflumilast Cream Vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials |
|
Topical roflumilast cream (ARQ-151) phase 3 plaque psoriasis study (DERMIS-1) Completed |
Phase: 3 | MOA: PDE4 inhibitor | Disease state: Plaque psoriasis | Investigational therapy: Roflumilast cream (ARQ-151) | Associated publications: Effect of Roflumilast Cream Vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials |